Abbott's Libre CGM Shows Significant Glucose Management Gains for Type 2 Diabetes Patients on Basal Insulin

Event summary

  • Abbott's FreeStyle Libre CGM technology reduced HbA1c levels by 0.6% and increased time in healthy glucose range by 2.5 hours daily for Type 2 diabetes patients on basal insulin, per the FreeDM2 study.
  • The 4-month UK study involved 303 participants across 24 clinical sites, showing significant improvements through self-management guided by real-time CGM insights.
  • An Italian study with 88 participants confirmed these findings, demonstrating better average glucose levels, more time in range, and improved quality of life after 3 months.
  • Only 18%-30% of basal insulin users currently meet HbA1c goals, contributing to $217 billion in annual diabetes healthcare costs.
  • Abbott aims to expand CGM reimbursement for basal insulin users, currently limited to those using multiple daily insulin injections in many regions.

The big picture

Abbott's study results position its FreeStyle Libre technology as a game-changer for Type 2 diabetes management, particularly for the large population on basal insulin who struggle to meet glucose targets. This reinforces the strategic value of CGM technology in chronic disease management and could reshape reimbursement policies. With approximately 8 million users globally, Abbott is well-positioned to capitalize on this growing demand for advanced diabetes care solutions.

What we're watching

Reimbursement Expansion
Whether Abbott can leverage these study results to secure broader CGM reimbursement for basal insulin users, potentially unlocking a significant market opportunity.
Market Penetration
The pace at which Abbott can convert the 63 million insulin-dependent Type 2 diabetes patients into Libre CGM users, given current low adoption rates.
Competitive Dynamics
How competitors like Dexcom and Medtronic may respond to Abbott's strengthened position in the CGM market for Type 2 diabetes management.